Lipocine Inc. Files 8-K
Ticker: LPCN · Form: 8-K · Filed: Sep 26, 2025 · CIK: 1535955
| Field | Detail |
|---|---|
| Company | Lipocine Inc. (LPCN) |
| Form Type | 8-K |
| Filed Date | Sep 26, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-k, filing, sec
TL;DR
Lipocine filed an 8-K on 9/26/25. Standard update.
AI Summary
Lipocine Inc. filed an 8-K on September 26, 2025, reporting on other events and financial statements. The filing does not detail specific transactions or financial figures but serves as a notification of these items.
Why It Matters
This filing indicates Lipocine Inc. is providing updates on its corporate activities and financial status to the SEC, which is standard procedure for public companies.
Risk Assessment
Risk Level: low — This is a routine filing with no immediate disclosed material events or financial changes.
Key Players & Entities
- Lipocine Inc. (company) — Registrant
- September 26, 2025 (date) — Date of Earliest Event Reported
- 675 Arapeen Drive, Suite 202 (address) — Principal Executive Offices
- Salt Lake City, Utah 84108 (address) — Principal Executive Offices
- 801-994-7383 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing for Lipocine Inc.?
The primary purpose is to report on 'Other Events' and 'Financial Statements and Exhibits' as of September 26, 2025.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is September 26, 2025.
What is Lipocine Inc.'s principal executive office address?
Lipocine Inc.'s principal executive office is located at 675 Arapeen Drive, Suite 202, Salt Lake City, Utah 84108.
What is the Commission File Number for Lipocine Inc.?
The Commission File Number for Lipocine Inc. is 001-36357.
Does this filing indicate any specific new material events or transactions?
The filing indicates 'Other Events' and 'Financial Statements and Exhibits' but does not specify the details of any new material events or transactions within the provided text.
Filing Stats: 467 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2025-09-26 09:31:48
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share LPCN The NASDAQ Stock Mar
Filing Documents
- form8-k.htm (8-K) — 40KB
- ex99-1.htm (EX-99.1) — 35KB
- form8-k_001.jpg (GRAPHIC) — 12KB
- ex99-1_001.jpg (GRAPHIC) — 278KB
- ex99-1_002.jpg (GRAPHIC) — 370KB
- ex99-1_003.jpg (GRAPHIC) — 190KB
- ex99-1_004.jpg (GRAPHIC) — 302KB
- ex99-1_005.jpg (GRAPHIC) — 176KB
- ex99-1_006.jpg (GRAPHIC) — 313KB
- ex99-1_007.jpg (GRAPHIC) — 233KB
- ex99-1_008.jpg (GRAPHIC) — 304KB
- ex99-1_009.jpg (GRAPHIC) — 349KB
- ex99-1_010.jpg (GRAPHIC) — 288KB
- ex99-1_011.jpg (GRAPHIC) — 163KB
- ex99-1_012.jpg (GRAPHIC) — 225KB
- ex99-1_013.jpg (GRAPHIC) — 237KB
- ex99-1_014.jpg (GRAPHIC) — 301KB
- ex99-1_015.jpg (GRAPHIC) — 256KB
- ex99-1_016.jpg (GRAPHIC) — 158KB
- ex99-1_017.jpg (GRAPHIC) — 251KB
- ex99-1_018.jpg (GRAPHIC) — 243KB
- ex99-1_019.jpg (GRAPHIC) — 314KB
- ex99-1_020.jpg (GRAPHIC) — 177KB
- ex99-1_021.jpg (GRAPHIC) — 257KB
- ex99-1_022.jpg (GRAPHIC) — 236KB
- ex99-1_023.jpg (GRAPHIC) — 331KB
- ex99-1_024.jpg (GRAPHIC) — 183KB
- ex99-1_025.jpg (GRAPHIC) — 295KB
- ex99-1_026.jpg (GRAPHIC) — 186KB
- ex99-1_027.jpg (GRAPHIC) — 183KB
- ex99-1_028.jpg (GRAPHIC) — 224KB
- ex99-1_029.jpg (GRAPHIC) — 117KB
- ex99-1_030.jpg (GRAPHIC) — 173KB
- ex99-1_031.jpg (GRAPHIC) — 202KB
- ex99-1_032.jpg (GRAPHIC) — 97KB
- ex99-1_033.jpg (GRAPHIC) — 258KB
- ex99-1_034.jpg (GRAPHIC) — 211KB
- ex99-1_035.jpg (GRAPHIC) — 233KB
- ex99-1_036.jpg (GRAPHIC) — 161KB
- ex99-1_037.jpg (GRAPHIC) — 183KB
- 0001493152-25-015081.txt ( ) — 12198KB
- lpcn-20250926.xsd (EX-101.SCH) — 3KB
- lpcn-20250926_lab.xml (EX-101.LAB) — 33KB
- lpcn-20250926_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LIPOCINE INC. Date: September 26, 2025 By: /s/ Mahesh V. Patel Mahesh V. Patel President and Chief Executive Officer